Empagliflozin Changes Urine Supersaturation by Decreasing pH and Increasing Citrate
… This post hoc analysis shows that SGLT2i may reduce kidney calciumcontaining stone risk by decreasing the RSR of CaP minerals in healthy subjects. This effect seems to be mediated by increased urinary citrate and reduced urinary pH. Prospective trials with kidney stone formers are needed to evaluate the effect of SGLT2i in secondary prevention of nephrolithiasis.